Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

10 Stocks on a Bankruptcy Watch

By Josh Enomoto, InvestorPlace Contributor

It’s no secret that the coronavirus pandemic has brought the global economy to its knees. But some companies have been hurt more than others, like these stocks to sell which might also suffer on a more permanent basis.

Why the Coronavirus Is a Double-Edged Sword for Aurora Cannabis

By Josh Enomoto, InvestorPlace Contributor

Beaten up for most of this year, Aurora stock finally looks interesting after encouraging results from the company’s fiscal Q3 earnings report. While still incredibly risky, ACB can move higher based on longer-term developments.

Visa Stock Jumped on Positive Vaccine News But It’s Not All That

By Josh Enomoto, InvestorPlace Contributor

With the possibility of an effective coronavirus vaccine recently revealed, blue-chip investments like V stock jumped higher. Still, the fine print suggests prospective buyers should remain cautious.

If Nio Skyrockets, You May Want to Thank President Trump

By Josh Enomoto, InvestorPlace Contributor

A lack of comprehensive EV infrastructure was among the many headwinds impacting Nio stock. But post-coronavirus, geopolitical rumblings may benefit NIO and other Chinese EV makers.

Marathon Oil Still Has a Long Way to Run Despite the Vaccine

By Josh Enomoto, InvestorPlace Contributor

The beleaguered oil market needs a lifeline and it may have gotten one from Moderna’s coronavirus vaccine. However, before diving into independent names like MRO stock, be sure to understand the risks.

Load More